share_log

Fresenius Medical Care Analyst Ratings

Fresenius Medical Care Analyst Ratings

费森尤斯医疗分析师评级
Benzinga ·  2023/07/13 12:47
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/13/2023 7.18% Truist Securities $26 → $28 Maintains Hold
05/10/2023 -0.48% Truist Securities $24 → $26 Maintains Hold
04/13/2023 -8.13% Truist Securities $22 → $24 Maintains Hold
02/23/2023 -15.79% Truist Securities $17 → $22 Maintains Hold
06/22/2022 3.35% Truist Securities $34 → $27 Maintains Hold
11/23/2021 HSBC Initiates Coverage On → Hold
11/17/2021 33.97% RBC Capital $42 → $35 Maintains Sector Perform
11/11/2021 Jefferies Upgrades Underperform → Hold
05/21/2020 83.73% SunTrust Robinson Humphrey $46 → $48 Maintains Buy
05/11/2020 76.08% SunTrust Robinson Humphrey $42 → $46 Maintains Buy
04/13/2020 60.77% SunTrust Robinson Humphrey $46 → $42 Maintains Buy
02/21/2020 76.08% CFRA $38 → $46 Upgrades Hold → Buy
01/21/2020 Jefferies Upgrades Hold → Buy
10/23/2019 Redburn Partners Downgrades Buy → Neutral
08/01/2019 BTIG Downgrades Buy → Neutral
06/20/2019 Barclays Upgrades Equal-Weight → Overweight
10/26/2018 UBS Upgrades Neutral → Buy
10/18/2018 DZ Bank Downgrades Buy → Hold
08/28/2018 HSBC Upgrades Hold → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
07/13/2023 7.18% Truist证券 $26→$28 维护 保持
2023年05月10日 -0.48% Truist证券 $24→$26 维护 保持
04/13/2023 -8.13% Truist证券 $22→$24 维护 保持
02/23/2023 -15.79% Truist证券 $17→$22 维护 保持
2022/06/22 3.35% Truist证券 $34→$27 维护 保持
2021年11月23日 - 汇丰银行 开始承保 →保留
2021年11月17日 33.97% 加拿大皇家银行资本 $42→$35 维护 行业表现
2021年11月11日 - 杰富瑞 升级 表现不佳的→保持
2020/05/21 83.73% SunTrust Robinson Humphrey $46→$48 维护
05/11/2020 76.08% SunTrust Robinson Humphrey $42→$46 维护
04/13/2020 60.77% SunTrust Robinson Humphrey $46→$42 维护
02/21/2020 76.08% CFRA $38→$46 升级 持有→购买
2020/01/21 - 杰富瑞 升级 持有→购买
2019年10月23日 - Redburn合作伙伴 评级下调 购买→中性
2019年08月01日 - BTIG 评级下调 购买→中性
2019年06月20日 - 巴克莱 升级 等重→超重
2018年10月26日 - 瑞银集团 升级 中性→购买
2018年10月18日 - 德国中央合作银行 评级下调 购买→Hold
2018年08月28日 - 汇丰银行 升级 持有→购买

What is the target price for Fresenius Medical Care (FMS)?

费森尤斯医疗保健(FMS)的目标价格是多少?

The latest price target for Fresenius Medical Care (NYSE: FMS) was reported by Truist Securities on July 13, 2023. The analyst firm set a price target for $28.00 expecting FMS to rise to within 12 months (a possible 7.18% upside). 4 analyst firms have reported ratings in the last year.

TRUIST证券于2023年7月13日报道了费森尤斯医疗保健公司(纽约证券交易所代码:FMS)的最新目标价。这家分析公司将目标价定为28.00美元,预计FMS将在12个月内上涨至7.18%。去年有4家分析公司公布了评级。

What is the most recent analyst rating for Fresenius Medical Care (FMS)?

费森尤斯医疗保健(FMS)的最新分析师评级是多少?

The latest analyst rating for Fresenius Medical Care (NYSE: FMS) was provided by Truist Securities, and Fresenius Medical Care maintained their hold rating.

费森尤斯医疗保健公司(纽约证券交易所代码:FMS)的最新分析师评级由Truist Securities提供,费森尤斯医疗保健公司维持其持有评级。

When is the next analyst rating going to be posted or updated for Fresenius Medical Care (FMS)?

费森尤斯医疗保健(FMS)的下一次分析师评级将于何时发布或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fresenius Medical Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fresenius Medical Care was filed on July 13, 2023 so you should expect the next rating to be made available sometime around July 13, 2024.

分析师在进行了广泛的研究后得出了股票评级,其中包括查阅公共财务报表,与费森尤斯医疗保健公司的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。费森尤斯医疗保健的上一次评级是在2023年7月13日提交的,因此您应该预计下一次评级将在2024年7月13日左右的某个时候提供。

Is the Analyst Rating Fresenius Medical Care (FMS) correct?

分析师对费森尤斯医疗保健(FMS)的评级正确吗?

While ratings are subjective and will change, the latest Fresenius Medical Care (FMS) rating was a maintained with a price target of $26.00 to $28.00. The current price Fresenius Medical Care (FMS) is trading at is $26.13, which is within the analyst's predicted range.

虽然评级是主观的,并将发生变化,但最新的费森尤斯医疗保健(FMS)评级保持不变,目标价在26.00美元至28.00美元之间。费森尤斯医疗保健(FMS)目前的交易价格为26.13美元,在分析师的预测范围内。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发